Figure 2.
Determination of optimal age-based starting dosages of topotecan. The final nonlinear mixed-effects model was used to perform Monte Carlo simulations of topotecan lactone plasma concentration in patients of different ages over a range of dosages. The topotecan lactone AUC calculated for each patient in the simulation was used to determine the probability of achieving the targeted 120–160 ng/mL*hr systemic exposure within each age group.